Comparison of the effects of enoxaparin and nadroparin on tumor angiogenesis in mice

Central-European Journal of Immunology

Volumn 31, Issue 1-2, 2006, Pages 70-74

  Wasiutyński, Aleksander ^a   Skopińska Rózewska, Ewa ^a   Jung, Leszek ^b   Sommer, Ewa ^a   Bany, Janusz ^c   Siwicki, Andrzej K ^d   Chorostowska Wynimko, Joanna ^e   Pra̧tnicki, Antoni ^a   Morton, Marcin ^a   Skurzak, Henryk ^f  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b INSTITUTE OF RHEUMATOLOGY   (Poland)

^c MILITARY INSTITUTE OF HYGIENE AND EPIDEMIOLOGY   (Poland)

^d UNIVERSITY OF WARMIA AND MAZURY IN OLSZTYN   (Poland)

^e NATIONAL TUBERCULOSIS AND LUNG DISEASES RESEARCH INSTITUTE   (Poland)

^f INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Angiogenesis; Cytokines; L 1 sarcoma; Low molecular weight heparins; Mice

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CYTOKINE; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFECT; DRUG INHIBITION; FEMALE; HISTOLOGY; ISOGRAFT; MALE; MOUSE; NEOPLASM; NONHUMAN; SARCOMA CELL; TUMOR GROWTH;

EID: 33750383497     PISSN: 14263912     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Folkman J, Taylor S, Spillberg C (1983): The role of heparin in angiogenesis. In: Development of the vascular system. Pitman books, London (Ciba Foundation symposium 100), pp. 132-149.
2. Norrby K (1993): Heparin and angiogenesis: a low-molecular-weight fraction inhibits and a high-molecular-weight fraction stimulates angiogenesis systemically. Haemostasis 23 (suppl): 141-149.
3. Norrby K, Ostergaard P (1996): Basic-fibroblast-growth factor - mediated de novo angiogenesis is more effectively suppressed by low-molecular-weight than by high-molecular-weight heparin. Int J Microcirc Clin Exp 16: 8-15.
4. Norrby K (2000): 2.5 kDa and 5.0 kDa heparin fragments specifically inhibit microvessel sprouting and network formation in VEGF165-mediated mammalian angiogenesis. Int J Exp Pathol 81: 191-198.
5. Bobek V, Kovarik J (2004): Antitumor and anti-metastatic effect of warfarin and heparins. Biomed Pharmacother 58: 213-219.
6. Castelli R, Porro F, Tarsia P (2004): The heparins and cancer: review of clinical trials and biological properties. Vasc Med 9: 205-213.
7. Jung L, Siwicki AK, Skopińska-Różewska, et al. (2005): Enoxaparine increases and fraxiparine decreases angiogenic activity of murine serum independently of the strain of mice. Pol J Environm Studies 14 (suppl II): 564-568.
8. Sidky YA, Auerbach R (1975): Lymphocyte-induced angiogenesis: a quantitative and sensitive assay of the graft-vs.-host reaction. J Exp Med 141: 1084-1100.
9. Skopińska-Różewska E, Sommer E, Demkow U, et al. (1997): Screening of angiogenesis inhibitors by modified tumor induced angiogenesis (TIA) test in lung cancer. Ann Acad Med Bialostocensis 42 (Suppl 1): 287-295.
10. Kragh M, Loechel F (2005): Non-anti-coagulant heparins: a promising approach for prevention of tumor metastasis (review). Int J Oncol 27: 1159-1167.
11. Klerk CP, Smorenburg SM, Otten HM, et al. (2005): The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23: 2119-2120.
12. Szende B, Paku S, Racz G, Kopper L (2005): Effect of Fraxiparine and heparin on experimental tumor metastasis in mice. Anticancer Res 25: 2869-2872.
13. Bobek V, Boubelik M, Fiserova A, et al. (2005): Anticoagulant drugs increase natural killer cell activity in lung cancer. Lung Cancer 47: 215-223.
14. Fareed J, Leong WL, Hoppensteadt DA, et al. (2004): Generic low-molecular-weight heparins: some practical considerations. Semin Thromb Hemost 30: 703-713.
15. Jung L, Skopińska-Różewska E, Małdyk P, et al. (2006): Enoxaparin treatment enhanced angiogenic activity of mouse and human serum. Central Eur J Immunol (in press).
16. Ahmad SA, Jung YD, Liu S, et al. (2002): The role of the microenvironment and intercellular cross-talk in tumor angiogenesis. Seminars Cancer Biol 12: 105-112.